Search

Coloplast A-S (Class B)

Ouvert

536.2 -2.01

Résumé

Variation du prix de l'action

24h

Actuel

Min

535.2

Max

547.6

Chiffres clés

By Trading Economics

Revenu

70M

875M

Ventes

2M

7B

P/E

Moyenne du Secteur

35.807

90.831

BPA

3.88

Rendement du dividende

4.01

Marge bénéficiaire

12.572

Employés

16,744

EBITDA

2B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+11.86% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

4.01%

2.20%

Prochains Résultats

6 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

7.5B

130B

Ouverture précédente

538.21

Clôture précédente

536.2

Coloplast A-S (Class B) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

19 janv. 2026, 16:17 UTC

Acquisitions, Fusions, Rachats

Zurich Insurance Makes $10 Billion Bid for U.K. Specialist Insurer Beazley -- Update

19 janv. 2026, 23:50 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over U.S.-Europe Relations -- Market Talk

19 janv. 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

19 janv. 2026, 22:29 UTC

Market Talk

China Infant Formula Market May Hold Up Despite Steep Drop in Births -- Market Talk

19 janv. 2026, 22:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 janv. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

19 janv. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

19 janv. 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

19 janv. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

19 janv. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

19 janv. 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

19 janv. 2026, 17:09 UTC

Market Talk

Global Equities Roundup: Market Talk

19 janv. 2026, 17:09 UTC

Market Talk

Copper Rises in Spite of Softer Dollar, Trade Concerns -- Market Talk

19 janv. 2026, 16:18 UTC

Market Talk

New Zealand Dollar Could Recover Against Swedish Krona -- Market Talk

19 janv. 2026, 16:12 UTC

Market Talk

Norwegian Krone's Recent Gains Are Unlikely to Last -- Market Talk

19 janv. 2026, 16:06 UTC

Acquisitions, Fusions, Rachats

LVMH: Deal Completion Subject to Customary Closing Conditions and Expected to Close in Around Two Months

19 janv. 2026, 16:04 UTC

Acquisitions, Fusions, Rachats

LVMH: Both Parties Aim to Set Up Strategic Cooperation in the Retail Sector

19 janv. 2026, 16:03 UTC

Acquisitions, Fusions, Rachats

LVMH, CTG Duty-Free Also Entered Into a MoU

19 janv. 2026, 16:02 UTC

Acquisitions, Fusions, Rachats

LVMH: Subscription to Be Made Upon Completion of Transaction

19 janv. 2026, 16:00 UTC

Acquisitions, Fusions, Rachats

LVMH: Capital Increase by Subscribing to Newly Issued H-shares Listed in Hong Kong

19 janv. 2026, 16:00 UTC

Market Talk

Term Premium on U.S. Treasurys Looks Too Low, Says Pictet AM -- Market Talk

19 janv. 2026, 15:58 UTC

Acquisitions, Fusions, Rachats

LVMH and the Miller Family Will Participate in a Capital Increase of CTG DutyFree

19 janv. 2026, 15:57 UTC

Acquisitions, Fusions, Rachats

LVMH: DFS Will Continue to Operate Its Other Luxury Travel Retail Operations Worldwide

19 janv. 2026, 15:57 UTC

Acquisitions, Fusions, Rachats

LVMH: Proceeds of Transaction Will Be Paid in Cash

19 janv. 2026, 15:56 UTC

Acquisitions, Fusions, Rachats

LVMH: CTG Duty-Free Will Run the Acquisition Through Its Subsidiary China Duty Free International Limited

19 janv. 2026, 15:53 UTC

Acquisitions, Fusions, Rachats

LVMH: Intangible Assets Include a Series of DFS Brands and IP for Exclusive Use in Greater China

19 janv. 2026, 15:52 UTC

Acquisitions, Fusions, Rachats

LVMH: CTG Duty-Free to Acquire the DFS Retail Stores in Hong Kong and Macau and Intangible Assets

19 janv. 2026, 15:51 UTC

Acquisitions, Fusions, Rachats

LVMH: DFS, CTG Duty-Free Reach Definitive Pact for CTG Duty-Free to Buy DFS' Travel Retail Unit in Hong Kong and Macau and Intangible Assets in Greater China

19 janv. 2026, 15:39 UTC

Market Talk

Canadian Dollar's Underperformance Looks Overstretched -- Market Talk

19 janv. 2026, 15:37 UTC

Market Talk

Bank of Canada Could Consider Cutting Rates if Underlying Inflation Slows Further -- Market Talk

Coloplast A-S (Class B) prévision

Objectif de Prix

By TipRanks

11.86% hausse

Prévisions sur 12 Mois

Moyen 901.38 DKK  11.86%

Haut 1,056 DKK

Bas 720 DKK

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

8 ratings

2

Achat

4

Maintien

2

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat